← Oncology Approval Tracker

FDA DECISION ·

Elahere

mirvetuximab soravtansine-gynx · ImmunoGen

Accelerated approvalNew therapyOvarian, fallopian tube and primary peritoneal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Mar 22, 2024

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with FRα-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after one to three previous systemic regimens, selected using an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

The original accelerated approval introduces FRα-directed therapy after platinum resistance.

What research teams should watch

Verify the assay and prior-line count. Coordinate eye examinations and ocular toxicity reporting.

PRIMARY RECORDS

Sources